Annual report
9341.TEDINET S100W2S5
Period2024-04-01 → 2025-03-31
Filed2025-06-23
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 150
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥10.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥8.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥6.5bn | 2022-04-01 → 2023-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥4.8bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥3.8bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥2.0bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Operating income | ¥2.3bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Ordinary income | ¥2.0bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥2.3bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.7bn | 2022-04-01 → 2023-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.1bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥804m | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.0bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥2.3bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.4bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.7bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.3bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥686m | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥629m | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥1.4bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Net income | ¥1.7bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Total assets | ¥8.5bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥8.2bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥5.4bn | at 2023-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥2.8bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.9bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥1.5bn | at 2025-03-31 | Cons. | Liabilities |
| Total liabilities | ¥2.2bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥7.0bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥6.0bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥4.0bn | at 2023-03-31d | Cons. | Net assets |
| Net assets / equity | ¥1.5bn | at 2022-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥777m | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥5.9bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥6.0bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥5.9bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.0bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.9bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.6bn | at 2022-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥1.2bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥1.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.2bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥624m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.1bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥276m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥94m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥113m | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥179m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥68m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥1.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥377m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.1bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥60m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥75m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥79.78 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥97.35 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥76.61 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥42.96 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥39.88 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥79.02 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥96.5 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥73.07 | 2022-04-01 → 2023-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥378.77 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥324.82 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥229.47 | at 2023-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥91.9 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥48.67 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 76.9% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.5% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 74.6% | at 2023-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 52.7% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.0% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 22.9% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 35.2% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 45.6% | 2022-04-01 → 2023-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 60.9% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 138.9% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 408 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 352 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 294 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 242 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 185 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥9.9bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥8.5bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥6.4bn | 2022-04-01 → 2023-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥4.7bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥3.6bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥2.0bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥2.3bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥2.0bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥2.3bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.7bn | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.0bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥774m | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.0bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥2.3bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥1.4bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥1.7bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥1.2bn | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥666m | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥605m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥8.4bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥8.1bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥5.3bn | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥2.7bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.8bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥1.5bn | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥2.1bn | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥6.9bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥6.0bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥4.0bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥1.4bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥738m | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥5.8bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥5.9bn | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥80.71 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥96 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥75.52 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥41.72 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥38.35 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥79.94 | 2024-04-01 → 2025-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥95.16 | 2023-04-01 → 2024-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥72.03 | 2022-04-01 → 2023-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥30 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥374.86 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥320.1 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥225.51 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥88.65 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥46.76 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 77.0% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.5% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 74.8% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 52.7% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.4% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 23.5% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 35.2% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 46.0% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 61.4% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 139.0% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 17,806,600 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 17,794,100 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 17,598,100 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 80,900 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 7,890 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 378 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 322 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 269 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 215 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 159 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 76
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2024-04-01 → 2025-03-31 | ¥5m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2024-04-01 → 2025-03-31 | ¥2m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2025-03-31 | 35 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2025-03-31 | ¥565m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2025-03-31 | ¥565m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2025-03-31 | ¥122m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2025-03-31 | ¥113m |
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥10m |
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥21m |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥6.4bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥1.8bn |
| Medical Platform Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥75m |
| Medical Platform Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥34m |
| Medical Platform Businessreportable segment | employees | at 2025-03-31 | 230 pure |
| Medical Platform Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥6.3bn |
| Medical Platform Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥6.3bn |
| Medical Platform Businessreportable segment | segment assets | at 2025-03-31 | ¥1.2bn |
| Medical Platform Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥3.1bn |
| Smart Clinic Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥38m |
| Smart Clinic Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥23m |
| Smart Clinic Businessreportable segment | employees | at 2025-03-31 | 89 pure |
| Smart Clinic Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥3.2bn |
| Smart Clinic Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥3.2bn |
| Smart Clinic Businessreportable segment | segment assets | at 2025-03-31 | ¥796m |
| Smart Clinic Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥579m |
| —segment total | capex | 2024-04-01 → 2025-03-31 | ¥113m |
| —segment total | depreciation | 2024-04-01 → 2025-03-31 | ¥57m |
| —segment total | employees | at 2025-03-31 | 319 pure |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥9.4bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥9.4bn |
| —segment total | segment assets | at 2025-03-31 | ¥2.0bn |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥3.7bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-04-01 → 2025-03-31 | ¥119m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-04-01 → 2025-03-31 | ¥59m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥10.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥10.0bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-03-31 | ¥2.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | ¥3.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2023-04-01 → 2024-03-31 | ¥3m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2023-04-01 → 2024-03-31 | ¥3m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2024-03-31 | ¥585m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2024-03-31 | ¥585m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2024-03-31 | ¥150m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2024-03-31 | ¥173m |
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥12m |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥16m |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥6.3bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥1.5bn |
| Medical Platform Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥31m |
| Medical Platform Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥33m |
| Medical Platform Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥5.4bn |
| Medical Platform Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥5.4bn |
| Medical Platform Businessreportable segment | segment assets | at 2024-03-31 | ¥1.0bn |
| Medical Platform Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥3.0bn |
| Smart Clinic Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥22m |
| Smart Clinic Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥21m |
| Smart Clinic Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥2.7bn |
| Smart Clinic Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥2.7bn |
| Smart Clinic Businessreportable segment | segment assets | at 2024-03-31 | ¥741m |
| Smart Clinic Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥680m |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥53m |
| —segment total | depreciation | 2023-04-01 → 2024-03-31 | ¥55m |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥8.1bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥8.1bn |
| —segment total | segment assets | at 2024-03-31 | ¥1.8bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥3.7bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-04-01 → 2024-03-31 | ¥56m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-04-01 → 2024-03-31 | ¥58m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥8.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥8.7bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-03-31 | ¥1.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥3.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2025-03-31 | 15 pure |
| Medical Platform Businessreportable segment | employees | at 2025-03-31 | 228 pure |
| Smart Clinic Businessreportable segment | employees | at 2025-03-31 | 81 pure |
| —segment total | employees | at 2025-03-31 | 309 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,392
| Item | Context | Value | Unit |
|---|---|---|---|
| Total assets (5-year summary) | Prior2YearInstant | 5414923000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 8199474000 | JPY |
| Total assets (5-year summary) | CurrentYearInstant | 8526196000 | JPY |
| Net assets per share (5-year summary) | Prior4YearInstant | 48.67 | |
| Net assets per share (5-year summary) | Prior3YearInstant | 91.90 | |
| Net assets per share (5-year summary) | Prior2YearInstant | 229.47 | |
| Net assets per share (5-year summary) | Prior1YearInstant | 324.82 | |
| Net assets per share (5-year summary) | CurrentYearInstant | 378.77 | |
| Basic earnings loss per share (5-year summary) | Prior4YearDuration | 39.88 | |
| Basic earnings loss per share (5-year summary) | Prior3YearDuration | 42.96 | |
| Basic earnings loss per share (5-year summary) | Prior2YearDuration | 76.61 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | 97.35 | |
| Basic earnings loss per share (5-year summary) | CurrentYearDuration | 79.78 | |
| Diluted earnings per share (5-year summary) | Prior4YearDuration | － | |
| Diluted earnings per share (5-year summary) | Prior3YearDuration | － | |
| Diluted earnings per share (5-year summary) | Prior2YearDuration | 73.07 | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | 96.50 | |
| Diluted earnings per share (5-year summary) | CurrentYearDuration | 79.02 | |
| Equity to asset ratio (5-year summary) | Prior4YearInstant | 0.410 | |
| Equity to asset ratio (5-year summary) | Prior3YearInstant | 0.527 | |
| Equity to asset ratio (5-year summary) | Prior2YearInstant | 0.746 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.705 | |
| Equity to asset ratio (5-year summary) | CurrentYearInstant | 0.769 | |
| Rate of return on equity (5-year summary) | Prior4YearDuration | 1.389 | |
| Rate of return on equity (5-year summary) | Prior3YearDuration | 0.609 | |
| Rate of return on equity (5-year summary) | Prior2YearDuration | 0.456 | |
| Rate of return on equity (5-year summary) | Prior1YearDuration | 0.352 | |
| Rate of return on equity (5-year summary) | CurrentYearDuration | 0.229 | |
| Price earnings ratio (5-year summary) | Prior4YearDuration | － | |
| Price earnings ratio (5-year summary) | Prior3YearDuration | － | |
| Price earnings ratio (5-year summary) | Prior2YearDuration | 18.1 | |
| Price earnings ratio (5-year summary) | Prior1YearDuration | 14.7 | |
| Price earnings ratio (5-year summary) | CurrentYearDuration | 12.4 | |
| Net cash provided by used in operating activities (5-year summary) | Prior4YearDuration | 1056024000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior3YearDuration | 623774000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior2YearDuration | 1203079000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior1YearDuration | 1822117000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | CurrentYearDuration | 1194851000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior4YearDuration | -68176000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior3YearDuration | -179061000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior2YearDuration | -113450000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YearDuration | -94238000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | CurrentYearDuration | -275933000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior4YearDuration | -75090000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior3YearDuration | 59885000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior2YearDuration | 1131226000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YearDuration | 376818000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | CurrentYearDuration | -1014917000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior4YearInstant | 1151428000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior3YearInstant | 1639503000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |